Peginterferon beta-1a
As of the edition of 20 October 2026, Peginterferon beta-1a is a protein: marketed, first approved in 2014 (EU); acts on IFNAR1 and IFNAR2; US protection ended in 2026.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Protein
- Brand name
- Plegridy
- First approved
- 18 July 2014 (EU)
- Approvals on record
- 7 in 2 regions
- Holder of the most recent approval
- Biogen; 2 holders in all
- Registered trials
- 21, 4 stopped early
- Disease areas
- Immune system; Nervous system; Chemically induced; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive
US protection
US protection ended in 2026.
US protection ended in 2026, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Biogen. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 4 | 2 | 0 |
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 3 | 6 | 3 | 1 | 2 |
| Phase 4 | 4 | 1 | 0 | 2 |
| All trials | 21 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Biogen | Applicant and Lead sponsor of trials | 2008 to now |